December 2024 in “Frontiers in Endocrinology” Continued research and awareness are needed to improve treatments for androgen-dependent diseases.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
89 citations
,
March 2001 in “Endocrine practice” The guidelines help doctors diagnose and treat hormone-related disorders in women.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
2 citations
,
April 2025 in “Cureus” Ki-67 levels do not predict treatment response in triple-negative breast cancer.
January 2023 in “Pharmaceutics” AA–TF#15 significantly promotes hair regrowth and could be an effective treatment for androgenic alopecia.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Surgical removal of an adrenal tumor resolved hormonal issues in a young woman.
11 citations
,
April 2018 in “Journal of Dermatology” Dutasteride safely treats hair loss without harming sexual function.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
January 2017 in “프로그램북(구 초록집)”
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
18 citations
,
September 1979 in “DMW - Deutsche Medizinische Wochenschrift” Diane is effective for treating acne, seborrhoea, androgenic alopecia, and mild hirsutism in women.
5 citations
,
June 2005 in “Journal of Clinical Oncology” PPX causes much less hair loss than traditional taxanes.
November 2014 in “PharmaTutor” Finasteride may help postmenopausal women with hair loss but is not effective for all and should be used cautiously in premenopausal women.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
3 citations
,
March 2013 in “International Journal of Clinical Practice” Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
1 citations
,
February 2009 in “Clinical and Experimental Dermatology” Hormone-replacement therapy improved a woman's skin condition known as lymphomatoid papulosis.
1 citations
,
September 2024 in “International Journal of Advanced Multidisciplinary Research and Studies” Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.
43 citations
,
March 2019 in “JAMA Dermatology” Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.
August 2020 in “European Journal of Dermatology” Dutasteride for hair loss can cause skin reactions like itchy red plaques.
1 citations
,
May 2021 in “Scientific Reports” Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
December 2025 in “International Journal of Innovative Technologies in Social Science” New treatments for androgenetic alopecia show promise but need more research for validation.
8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
49 citations
,
September 1986 in “British Journal of Dermatology” Hidradenitis suppurativa improves with antiandrogen therapy.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
March 2026 in “Research Square”
September 2014 in “Springer eBooks” The document concludes that breast pain should be managed with personalized treatment, starting with non-drug methods and progressing to medication if necessary, while considering side effects and patient needs.
18 citations
,
March 2002 in “The journal of investigative dermatology/Journal of investigative dermatology” Estrogen increases blood vessel growth factor production, while testosterone blocks this increase.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.